Matrix metalloproteinases in atherosclerosis: Role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 173-183

  Vacek, Thomas P ^a   Rehman, Shahnaz ^a   Neamtu, Diana ^a   Yu, Shipeng ^a   Givimani, Srikanth ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; BAICALEIN; CILOSTAZOL; COLLAGENASE 3; GELATINASE A; GELATINASE B; HOMOCYSTEINE; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRILAT; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MONTELUKAST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N(G) METHYLARGININE; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RESVERATROL; ROSUVASTATIN; SMALL INTERFERING RNA; STROMELYSIN; STROMELYSIN 2; TETRACYCLINE;

AORTA INJURY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CAROTID ARTERY INJURY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; VASODILATATION; ANIMAL; BLOOD VESSEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

ANIMALS; ATHEROSCLEROSIS; BLOOD VESSELS; ENZYME ACTIVATION; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; HYDROGEN SULFIDE; MATRIX METALLOPROTEINASES; NITRIC OXIDE; OXIDATIVE STRESS; PHENOTYPE; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VASODILATION;

EID: 84924551202     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S68415     Document Type: Article

References (60)

1. Urso C, Caimi G. Oxidative stress and endothelial dysfunction]. Minerva Med. 2011;102(1):59-77. Italian.
2. Van Assche T, Hendrickx J, Crauwels HM, et al. Transcription profles of aortic smooth muscle cells from atherosclerosis-prone and - resistant regions in young apolipoprotein E-deficient mice before plaque development. J Vasc Res. 2011;48(1):31-42.
3. Filipovic N, Rosic M, Tanaskovic I, Parodi O, Fotiadis D. Computer simulation and experimental analysis of LDL transport in the arteries. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:195-198.
4. Yang H, Zhang L, Xiong X, Liu Y. Specifc adhesion and accumulation of VCAM-1-targeted ultrasound microbubbles to infammatory endothe-lial cells under hemodynamic shear fow simulation. J Control Release. 2011;152 Suppl 1:e227-e229.
5. Zhang X, Liu X, Shang H, Xu Y, Qian M. Monocyte chemoattractant protein-1 induces endothelial cell apoptosis in vitro through a p53- dependent mitochondrial pathway. Acta Biochim Biophys Sin (Shanghai). 2011;43(10):787-795.
6. Xiao N, Yin M, Zhang L, et al. Tumor necrosis factor-alpha defciency retards early fatty-streak lesion by infuencing the expression of infam-matory factors in apoE-null mice. Mol Genet Metab. 2009;96(4): 239-244.
7. Razavian M, Tavakoli S, Zhang JS, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med. 2011;52(11):1795-1802.
8. Stary HC, Chandler AB, Dinsmore RE, et al. A defnition of advanced types of atherosclerotic lesions and a histological classifcation of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995;15(9):1512-1531.
9. Kim D, Lee D, Jang YL, et al. Facial amphipathic deoxycholic acid- modifed polyethyleneimine for effcient MMP-2 siRNA delivery in vascular smooth muscle cells. Eur J Pharm Biopharm. 2012;81(1):14-23.
10. Kaneko H, Anzai T, Horiuchi K, et al. Tumor necrosis factor-alpha converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218(2):470-478.
11. Kuzuya M, Nakamura K, Sasaki T, Cheng X W, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-defcient mice. Arterioscl Thromb Vasc Biol. 2006;26(5): 1120-1125.
12. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005;102(43):15575-15580.
13. Thomas AC, Newby AC. Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice. J Vasc Res. 2010;47(4):299-308.
14. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009;105(9):921-929.
15. Liu D, Ge S, Zhou G, et al. Montelukast inhibits matrix metallopro-teinases expression in atherosclerotic rabbits. Cardiovasc Drugs Ther. 2009;23(6):431-437.
16. Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-defcient mice. Arch Med Res. 2009;40(5):345-351.
17. Chuang S Y, Yang SH, Chen T Y, Pang JH. Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells. Eur J Pharmacol. 2011;670(2-3): 419-426.
18. Heo SH, Cho CH, Kim HO, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. J Clin Neurol. 2011;7(2): 69-76.
19. Lehrke M, Greif M, Broedl UC, et al. MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol. 2009;8:50.
20. Orbe J, Barrenetxe J, Rodriguez JA, et al. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fbrinolysis via a thrombin-activatable fbrinolysis inhibitor-mediated mechanism. Circulation. 2011;124(25):2909-2919.
21. Bini A, Wu D, Schnuer J, Kudryk BJ. Characterization of stromelysin 1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metal-loproteinase (MT1-MMP) derived fbrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late-stage digest fragments. Biochemistry. 1999;38(42):13928-13936.
22. Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H. Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fbrinogen and factor XII. J Biol Chem. 2000;275(42): 33008-33013.
23. Orbe J, Rodríguez JA, Calvayrac O, et al. Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation. Arterioscler Thromb Vasc Biol. 2009;29(12):2109-2116.
24. Lorente L, Martín MM, Labarta L, et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009;13(5):R158.
25. Orbe J, Montero I, Rodríguez JA, Beloqui O, Roncal C, Páramo JA. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost. 2007;5(1):91-97.
26. Quillard T, Tesmenitsky Y, Croce K, et al. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(11): 2464-2472.
27. Wågsäter D, Zhu C Y, Björkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the LdlrApob100/100 mouse. Int J Mol Med. 2011;28(2):247-253.
28. Lemaître V, Dabo AJ, D’Armiento J. Cigarette smoke components induce matrix metalloproteinase-1 in aortic endothelial cells through inhibition of mTOR signaling. Toxicol Sci. 2011;123(2):542-549.
29. Eefting D, Seghers L, Grimbergen JM, et al. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res. 2010;88(2):367-375.
30. Eefting D, de Vries MR, Grimbergen JM, Karper JC, van Bockel JH, Quax PH. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metallopro-teinase-1 linked to the amino terminal fragment of urokinase (TIMP-1. ATF), a cell-surface directed matrix metalloproteinase inhibitor. J Vasc Surg. 2010;51(2):429-437.
31. Basu P, Sen U, Tyagi N, Tyagi SC. Blood fow interplays with elastin: collagen and MMP:TIMP ratios to maintain healthy vascular structure and function. Vasc Health Risk Manag. 2010;6:215-228.
32. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 2011;31(9):e35-e44.
33. Bench TJ, Jeremias A, Brown DL. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease. Pharmacol Res. 2011;64(6):561-566.
34. Gaubatz J W, Ballantyne CM, Wasserman BA, et al. Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study. Arterioscler Thromb Vasc Biol. 2010;30(5):1034-1042.
35. Jefferis BJ, Whincup P, Welsh P, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2010;208(2):557-563.
36. Wang L, Ma YT, Xie X, et al. Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clin Appl Thromb Hemost. 2012;18(1):72-78.
37. Hu XF, Jin X P, Hu P Y, et al. Association of a functional polymorphism in the MMP7 gene promoter with susceptibility to vulnerable carotid plaque in a Han Chinese population. Clin Chem Lab Med. 2011;49(10): 1735-1741.
38. Jguirim-Souissi I, Jelassi A, Slimani A, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-12 gene polymorphisms and the outcome of coronary artery disease. Coron Artery Dis. 2011;22(6): 388-393.
39. Djurić TL, Stanković A, Končar I, et al. Association of MMP-8 promoter gene polymorphisms with carotid atherosclerosis: preliminary study. Atherosclerosis. 2011;219(2):673-678.
40. Djurić T, Zivković M, Stanković A, et al. Plasma levels of matrix metalloproteinase-8 in patients with carotid atherosclerosis. J Clin Lab Anal. 2010;24(4):246-251.
41. Ghaderian SM, Najar RA, Panah AS. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis. 2010;21(6): 330-335.
42. Moshal KS, Sen U, Tyagi N, et al. Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol. 2006;290(3): C883-C891.
43. Bescond A, Augier T, Chareyre C, Garçon D, Hornebeck W, Charpiot P. Infuence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun. 1999;263(2):498-503.
44. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens. 2002;15(2 Pt 1):157-163.
45. Liu F, Zhang J, Yu S, et al. Effect of folate on neointima formation and matrix metalloproteinase-9 expression after balloon injury in hyperhomocysteinemic rabbits. Int J Cardiol. 2008;131(1):59-65.
46. Ovechkin AV, Tyagi N, Sen U, et al. 3-Deazaadenosine mitigates arterial remodeling and hypertension in hyperhomocysteinemic mice. Am J Physiol Lung Cell Mol Physiol. 2006;291(5):L905-L911.
47. Sen U, Tyagi N, Kumar M, Moshal KS, Rodriguez WE, Tyagi SC. Cystathionine-beta-synthase gene transfer and 3-deazaadenosine ameliorate infammatory response in endothelial cells. Am J Physiol Cell Physiol. 2007;293(6):C1779-C1787.
48. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93(4):280-291.
49. Breen DM, Dolinsky V W, Zhang H, et al. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis. 2012;222(2): 375-381.
50. Nee L, O’Connell S, Nolan S, Ryan M P, McMorrow T. Nitric oxide involvement in TNF-alpha and IL-1 beta-mediated changes in human mesangial cell MMP-9 and TIMP-1. Nephron Exp Nephrol. 2008; 110(2):e59-e66.
51. Vacek T P, Qipshidze N, Tyagi SC. Hydrogen sulfde and sodium nitroprusside compete to activate/deactivate MMPs in bone tissue homogenates. Vasc Health Risk Manag. 2013;9:117-123.
52. Guo XG, Uzui H, Mizuguchi T, Ueda T, Chen JZ, Lee JD. Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fbroblasts induced by interleukin-1β via NO-dependent pathway. Int J Cardiol. 2008;126(3):414-420.
53. Shin CY, Lee WJ, Choi JW, et al. Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide. 2007;16(4): 425-432.
54. Egi K, Conrad NE, Kwan J, Schulze C, Schulz R, Wildhirt SM. Inhibition of inducible nitric oxide synthase and superoxide production reduces matrix metalloproteinase-9 activity and restores coronary vasomotor function in rat cardiac allografts. Eur J Cardiothorac Surg. 2004;26(2):262-269.
55. Choe TB, Lee BC, Park IC. Inhibition of matrix metalloproteinase-1 and -2 expression using nitric oxide synthase inhibitors in UV-irradiated human dermal fbroblasts. J Cosmet Sci. 2003;54(3):229-238.
56. Sen U, Sathnur PB, Kundu S, et al. Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovas-cular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol. 2012;303(1):C41-C51.
57. Vacek T P, Gillespie W, Tyagi N, Vacek JC, Tyagi SC. Hydrogen sulfde protects against vascular remodeling from endothelial damage. Amino Acids. 2010;39(5):1161-1169.
58. Yang G, Li H, Tang G, et al. Increased neointimal formation in cystathionine gamma-lyase defcient mice: role of hydrogen sulfde in α5β11-integrin and matrix metalloproteinase-2 expression in smooth muscle cells. J Mol Cell Cardiol. 2012;52(3):677-688.
59. Givvimani S, Munjal C, Gargoum R, et al. Hydrogen sulfde mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol. 2011;110(4):1093-1100.
60. Hongfang J, Cong B, Zhao B, et al. Effects of hydrogen sulfde on hypoxic pulmonary vascular structural remodeling. Life Sci. 2006; 78(12):1299-1309.